Tel: 01789 267520

CK-2127107 (Cytokinetics) Clinical Trial Updates

2017

CYTOKINETICS DRUG AWARDED ORPHAN DRUG DESIGNATION IN THE US

Cytokinetics initiates second cohort in Phase 2 Trial of CK-2127107


2016

CYTOKINETICS INITIATES PHASE II TRIAL OF POTENTIAL SMA DRUG